Other languages AnaptysBio, Inc.

Equities

ANAB

US0327241065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
24.34 ^USD	+14.27%		+26.90%	+13.63%

Apr. 16	Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	MT
Apr. 11	Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AnaptysBio Shares Jump on Upgrade by Wedbush	Mar. 12
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	Feb. 16
GSK : l'UE approuve Jemperli dans le cancer de l'endomètre	Dec. 11
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	Nov. 27
AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
AnaptysBio's Phase 3 Trial of Imsidolimab to Treat Generalized Pustular Psoriasis Meets Primary Endpoint	23-10-09
AnaptysBio's skin disease drug meets main goal in late-stage study	23-10-09
AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis	23-10-09
AnaptysBio, Inc. Announces Board Changes	23-09-18
AnaptysBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer	23-07-31
AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
AnaptysBio, Inc. Announces Board Changes	23-04-06
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01
Sector Update: Health Care Stocks Steady Friday Afternoon While Other Sectors Rebound	23-01-13
Sector Update: Health Care Standing Firm as Broader Markets Catch Up	23-01-13
AnaptysBio Approves $50 Million Share Buyback Plan; Stock Gains	23-01-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AnaptysBio, Inc.

Equities

ANAB

US0327241065

Other languages

Filters